Waxman eyeing off-label drug, stent use

Share this article:
A congressional committee has begun an examination into the off-label use of drugs and heart stents. California Democrat Henry Waxman, chairman of the House Committee on Oversight and Government Reform, has asked three drugmakers for marketing materials for drugs that have come under scrutiny over whether they have been promoted for unapproved uses. The companies include: Eli Lilly, whose antipsychotic Zyprexa achieved $4.4 billion in 2006 and was the company’s best-selling Rx product; and AstraZeneca, which makes schizophrenia drug treatment Seroquel and Cephalon, whose marketing of painkillers Actiq and Fentora has been under investigation by the Connecticut attorney general. The committee also asked Boston Scientific and Johnson & Johnson’s Cordis Unit, the only makers of drug-coated stents sold in the US, to submit marketing materials and clinical data. Approximately 60% of drug-coated stents, which prop open clogged arteries, are used off-label.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.